Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SX
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
Volume
10.09K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SX
SXTP
SX
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
News
·
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Mkt Cap
$3.2M
Volume
10.09K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals announced a private placement of 574,713 shares at $1.74 per share, expected to raise approximately $1.0 million in gross proceeds before fees. The offering includes series A and B warrants with exercise prices of $1.49 per share. The company plans to use net proceeds for working capital and general corporate purposes.
GlobeNewswire Inc. · Jul 30, 2026
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.
GlobeNewswire Inc. · Nov 13, 2025
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
60 Degrees Pharmaceuticals has introduced a new 8-count bottle format for its malaria prevention drug ARAKODA, expanding options for healthcare professionals and travelers.
GlobeNewswire Inc. · Jun 4, 2025
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
Sixty Degrees Pharmaceuticals announced that it will import a limited quantity of KODATEF® (tafenoquine) from Australia to ensure the continuity of ARAKODA® (tafenoquine) supply in the U.S. ARAKODA and KODATEF are identical products, and the company is taking this proactive step to maintain the availability of tafenoquine for malaria prophylaxis.
GlobeNewswire Inc. · Feb 11, 2025
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.
Benzinga · Jan 29, 2025
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
60 Degrees Pharmaceuticals announced a promotional pilot for its antimalarial drug ARAKODA, which aims to increase brand awareness and utilization through virtual sales outreach and a co-pay program.
GlobeNewswire Inc. · Oct 3, 2024
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
60 Degrees Pharmaceuticals, Inc. has regained compliance with the Nasdaq's minimum bid price requirement, maintaining a closing price of $1.81 per share for at least 10 consecutive trading days.
GlobeNewswire Inc. · Aug 28, 2024
Gold Down 2%; SLB Posts Upbeat Earnings - Benzinga
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points. Schlumberger reported better-than-expected second-quarter results, with revenue and adjusted EPS beating consensus estimates.
Benzinga · Jul 19, 2024
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Intuitive Surgical reported better-than-expected Q2 results, causing its shares to rise 6.7% in premarket trading. Several other stocks also saw significant premarket movements, both positive and negative.
Benzinga · Jul 19, 2024
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
GlobeNewswire Inc. · May 15, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SX
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
SXTP
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SXTP yet.
Related Tickers
Earnings